INDRAMEDCO · NSE
Indraprastha Medical Corporation Limited
₹362.9
-0.21% (-₹0.75)
Prev. close
₹363.65
Volume
1,34,873
Delivery %
65.1%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Indraprastha Medical Corporation Limited
Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, neonatology, nephrology, nuclear medicine, ophthalmology, pediatric sciences, urology, and plastic surgery, as well as pediatric urology and surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology and radio diagnosis, respiratory, rheumatology, spine surgery, urology and andrology, cardiology, oncology, emergency, gastroenterology, neuroscience, critical care, orthopedics, robotic surgery, and organ transplant, as well as laboratory services, interventional medicine, preventive medicine, and sleep medicine. Indraprastha Medical Corporation Limited was founded in 1983 and is based in New Delhi, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. Shivakumar Pattabhiraman ACA, B Com, CWA, Grad.
Headquarters
New Delhi
Employees
3,000
Website
apollohospitals.com/delhi/Exchange
View on NSE ↗Key stats
Market cap
₹3,326.81 Cr
P/E ratio (TTM)
17.7
Dividend yield
1.10%
EPS (TTM)
₹20.51
Beta (1Y · daily vs NIFTY 50)
1.23
Beta (5Y · monthly vs NIFTY 50)
1.18
Shares float
4.01 Cr
EPS · quarter ended Jun 2026
₹6.09
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 3.2% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹613.38 Cr | ₹888.16 Cr | ₹1,098.67 Cr | ₹1,244.70 Cr | ₹1,356.36 Cr | ₹1,482.51 Cr | |
| EBITDA | ₹40.95 Cr | ₹117.42 Cr | ₹160.73 Cr | ₹210.25 Cr | ₹266.92 Cr | ₹295.67 Cr |
| ₹2.33 Cr | ₹58.62 Cr | ₹86.15 Cr | ₹123.96 Cr | ₹160.99 Cr | ₹183.62 Cr | |
| Diluted EPS | ₹0.25 | ₹6.39 | ₹9.4 | ₹13.52 | ₹17.56 | ₹20.03 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹432.00 Cr | ₹462.00 Cr | ₹555.00 Cr | ₹723.00 Cr | ₹852.00 Cr | ₹991.00 Cr | |
| — | — | ₹2.48 Cr | ₹33.95 Cr | ₹32.76 Cr | ₹36.86 Cr | |
| Stockholders' equity | ₹273.00 Cr | ₹326.00 Cr | ₹380.00 Cr | ₹478.00 Cr | ₹597.00 Cr | ₹741.00 Cr |
CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹27.90 Cr | ₹71.29 Cr | ₹144.47 Cr | ₹200.15 Cr | ₹156.75 Cr | ₹167.44 Cr | |
| Investing cash flow | ₹-20.16 Cr | ₹-51.10 Cr | ₹-107.91 Cr | ₹-158.43 Cr | ₹-110.99 Cr | ₹-177.61 Cr |
| ₹-3.15 Cr | ₹-3.37 Cr | ₹-26.04 Cr | ₹-32.38 Cr | ₹-45.88 Cr | ₹-46.38 Cr | |
| Capital expenditure | ₹-21.00 Cr | ₹-29.00 Cr | ₹-45.00 Cr | ₹-69.00 Cr | ₹-36.00 Cr | ₹-60.00 Cr |
| End cash position | ₹24.92 Cr | ₹41.74 Cr | ₹52.26 Cr | ₹61.60 Cr | ₹61.48 Cr | ₹4.93 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Mar 21–Jun 26(21Q) |
|---|---|
| Promoter | 51.00% |
| Public | 49.00% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Indraprastha Medical Corporation Limited | ₹3,333.69 Cr | ₹362.9 | 17.7 | 4.50 | 24.8% | 0.05 | +9.0% | -23.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 28
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
7 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Indraprastha Medical Corporation standalone net profit rises 8.53% in the June 2026 quarter
business-standard.com · 1 month ago